Want to see JP:4554 full AI Analyst Report?
4554 Stock Chart & Stats
¥1888.00
-¥22.00(-1.41%)
At close: 4:00 PM EST
¥1888.00
-¥22.00(-1.41%)
Day’s Range― - ―
52-Week Range¥1,321.00 - ¥2,559.00
Previous CloseN/A
Volume88.50K
Average Volume (3M)86.41K
Market Cap
¥49.38B
Enterprise Value¥78.94B
Total Cash (Recent Filing)¥10.89B
Total Debt (Recent Filing)¥29.62B
Price to Earnings (P/E)18.9
Beta0.88
Next Earnings
Aug 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield2.39%
Share Statistics
EPS (TTM)98.82
Shares Outstanding26,541,100
10 Day Avg. Volume111,080
30 Day Avg. Volume86,410
Financial Highlights & Ratios
PEG Ratio-0.24
Price to Book (P/B)0.80
Price to Sales (P/S)0.73
P/FCF Ratio9.88
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)107.2
Revenue Forecast (FY)¥63.00B
Bulls Say, Bears Say
Bulls Say
Consistent Revenue GrowthFuji Pharma's consistent revenue growth reflects steady prescription volume and product commercialization in its core Japanese market. Durable top-line expansion supports scale benefits, ongoing R&D and commercialization funding, and provides a stable base for multi-quarter cash generation.
Gross Margin ResilienceA solid gross profit margin indicates effective manufacturing and cost control across both in-house and licensed products. This structural margin strength helps absorb SG&A and R&D variability, giving the business longer-term earnings durability even if operating margins wobble.
Improved Free Cash FlowImproving free cash flow and a better free-cash-flow-to-net-income ratio show enhanced cash generation and management. Persistent FCF supports reinvestment in product development and licensing, funds working capital needs, and provides capacity to reduce leverage without depending on external financing.
Bears Say
Rising LeverageAn increasing debt-to-equity trend raises financial risk and reduces flexibility to fund R&D or acquisitions. Higher leverage increases interest expense sensitivity to rates and amplifies downside during revenue or margin stress, constraining strategic options over the medium term.
Margin VolatilityRecent weakening and variability in EBIT and net margins suggest exposure to pricing, reimbursement or cost pressures in its specialty portfolio. Persistent margin swings can undermine sustainable earnings, complicate planning and reduce the predictability of cash available for investment or deleveraging.
Weaker Operating Cash ConversionOperating cash flow lagging net income points to weaker earnings-to-cash conversion, which can signal working capital strain or non-cash accounting differences. Poor conversion risks pressuring liquidity, increasing reliance on borrowing, and limiting the firm's ability to fund growth or reduce debt sustainably.
Fuji Pharma Co., Ltd. News
4554 FAQ
What was Fuji Pharma Co., Ltd.’s price range in the past 12 months?
Fuji Pharma Co., Ltd. lowest stock price was ¥1321.00 and its highest was ¥2559.00 in the past 12 months.
What is Fuji Pharma Co., Ltd.’s market cap?
Fuji Pharma Co., Ltd.’s market cap is ¥49.38B.
When is Fuji Pharma Co., Ltd.’s upcoming earnings report date?
Fuji Pharma Co., Ltd.’s upcoming earnings report date is Aug 06, 2026 which is in 23 days.
How were Fuji Pharma Co., Ltd.’s earnings last quarter?
Fuji Pharma Co., Ltd. released its earnings results on May 12, 2026. The company reported ¥15.47 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Fuji Pharma Co., Ltd. overvalued?
According to Wall Street analysts Fuji Pharma Co., Ltd.’s price is currently Overvalued.
Does Fuji Pharma Co., Ltd. pay dividends?
Fuji Pharma Co., Ltd. pays a Semiannually dividend of ¥26 which represents an annual dividend yield of 2.39%. See more information on Fuji Pharma Co., Ltd. dividends here
What is Fuji Pharma Co., Ltd.’s EPS estimate?
Fuji Pharma Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Fuji Pharma Co., Ltd. have?
Fuji Pharma Co., Ltd. has 26,541,100 shares outstanding.
What happened to Fuji Pharma Co., Ltd.’s price movement after its last earnings report?
Fuji Pharma Co., Ltd. reported an EPS of ¥15.47 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 0.085%.
Which hedge fund is a major shareholder of Fuji Pharma Co., Ltd.?
Currently, no hedge funds are holding shares in JP:4554
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Fuji Pharma Co., Ltd.
Fuji Pharma Co., Ltd. is a pharmaceutical company that operates globally, focusing on the complete spectrum of drug development, from initial research and discovery through manufacturing and commercialization. Its comprehensive product line includes various medical solutions such as injectable medications, oral therapeutics, topical treatments, and a range of diagnostic tools. Beyond its core pharmaceutical offerings, Fuji Pharma also specializes in women's healthcare products, advanced in vitro diagnostic technologies, and acute medical intervention solutions. The company further contributes by disseminating valuable pharmaceutical and general health information. Founded in 1965, Fuji Pharma Co., Ltd. has its corporate headquarters located in Tokyo, Japan.
Technical Analysis
Mochida Pharmaceutical Co., Ltd.
―
Fuso Pharmaceutical Industries,Ltd.
―
KYORIN Pharmaceutical Co.,Ltd.
―
Daito Pharmaceutical Co., Ltd.
―
ASKA Pharmaceutical Holdings Co., Ltd.
―
Options Prices
Currently, No data available
---